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Summary Endovascular stroke treatment is a rapidly evolving ﬁeld in neurointerventions. The
article reviews the evolution of the different mechanical thrombolysis and stenting techniques
and their working principles for endovascular vessel recanalization and reviews the data on theMechanical
thrombectomy;
Endovascular stroke
treatment;
outcome after acute stroke treatment.
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ntroduction
schemic stroke is one of the leading causes of disability
nd mortality in industrialized countries. Patient outcome
ainly depends on the time span between onset of symp-
oms and revascularization, recanalization rate and the
ccurrence of symptomatic intracranial hemorrhage (sICH)
1]. Therefore, fast and effective reperfusion in combi-
ation with a low rate of sICH is the key to successful
troke treatment. Systemic thrombolysis with intravenously
dministered tissue plasminogen activator (IV rtPA) and local
ntra-arterial thrombolysis (IAT) have been shown to be
ffective to improve patient outcome. However, the time
indow for treatment and the recanalization rate of both
Abbreviations: sICH, symptomatic intracranial hemorrhage; IV
tPA, intravenously administered tissue plasminogen activator; IAT,
ocal intra-arterial thrombolysis; PTA, percutaneous angioplasty;
IHSS, National Institute of Health Stroke Scale; FDA, Food and Drug
dministration.
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Open access under CC BY-NC-ND license.ethods are limited [2—4]. Furthermore, the application of
hrombolytic drugs increases the risk of sICH [5]. Moreover,
ecanalization rate is dependent on the site of occlusion:
roximal occlusions of large brain supplying vessels such
s the internal carotid artery have a limited recanalization
ate after either IV rtPA or IAT [3,4]. Therefore, the aim of
echanical recanalization approaches is to improve recanal-
zation rates, reduce the time to recanalization and further
xpand the window of opportunity. Furthermore, the waiv-
ng of thrombolytic drugs is considered to reduce the rate
f symptomatic intracranial hemorrhage.
echanical treatment approaches
ifferent techniques and approaches have been advocated
or mechanical thrombolysis in acute stroke treatment,
hich can be divided into: immediate ﬂow restoration using
elf-expandable stents and thrombectomy.
tent recanalizationlacement of a permanent intracranial stent achieves imme-
iate ﬂow restoration and recanalization by compressing
he thrombus against the vessel wall. Stenting allows fast
nd effective recanalization without the need of repetitive
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passing of the occlusion site and retrieval attempts. How-
ever, this concept has some disadvantages in general and
especially in the setting of acute stroke treatment. Throm-
bus compression may lead to permanent side branch or
perforator occlusion. Moreover, permanent stent placement
needs double platelet anti-aggregation medication in order
to prevent in-stent thrombosis and re-occlusion. This pre-
ventive medication may increase the risk of sICH in the
setting of acute stroke [6]. Furthermore, an in-stent re-
stenosis rate of bare metal stents has been reported in
up to 32% in the treatment of intracranial arteriosclerotic
stenosis after a follow-up period of 9 months [7]. The
use of different stent systems has been reported in case
reports and small case series. In general, self-expandable
stents are preferentially used over balloon-mounted
stents.
Recanalization rates are reported to be between 79%
and 92% with moderate clinical outcome in 33—50% [8,9].
The Stent-Assisted Recanalization in Acute Ischemic Stroke
(SARIS) trial is the ﬁrst FDA approved prospective trial inves-
tigating stenting in acute stroke treatment. 20 patients
(mean NIHSS 14) were included within 6 h after symptom
onset. Recanalization rate was 100% with adjuvant thera-
pies such as angioplasty, IV tPA and IAT applied in 63% of
patients. Moderate clinical outcome was achieved in 60% of
patients [10,11].
Despite the high recanalization rate reported in these
studies, the use of intracranial stenting in acute stroke
treatment is debatable due to the risks associated with
permanent stent deployment and the recent success of
thrombectomy. However, stenting has a clear value in selec-
tive cases of rescue therapy.
Mechanical thrombectomy
All mechanical thrombectomy devices are delivered by
endovascular access proximal to the occlusion site. The var-
ious systems can be divided into 3 major groups according
to where they apply mechanical force on the thrombus:
(a) Proximal devices apply force to the proximal base of
the thrombus. This group includes various aspiration
catheters and systems.
b) Distal devices approach the thrombus proximally but
then are advanced by microguidewire and micro-
catheter across the thrombus to be unsheathed behind
it, where force is applied to the distal base of the
thrombus. This group includes brush-like, basket-like or
coil-like devices.
(c) The most recently developed devices include stent-like
devices, which are placed across the thrombus at the
occlusion site, deployed within the thrombus and then
are retrieved. This group includes various types of self-
expandable, retrievable, stent-like devices, so-called
stent retrievers.
Proximal thrombectomy using thrombus aspiration
Vascular access is usually gained with a 7—8-F sheath. After
placement of the guiding catheter, a large dedicated aspira-
tion catheter (4—5-F) ﬂexible enough to pass the tortuosity
of the cranial vessels (e.g. carotid siphon) is navigated to
b
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b55
he proximal surface of the thrombus. Aspiration force is
pplied to the thrombus using a 60-ml syringe. The aspi-
ation catheter is then retrieved under constant negative
ressure to avoid loss of thrombus material. This approach
mits repetitive passing of the occlusion site and after each
etrieval of clot fragments, the procedure can be repeated.
he advantages of this approach are that it is mechanically
imple, fast to apply and inexpensive. Therefore, it is widely
sed, especially in proximal occlusions when the target ves-
el has a large diameter and an anatomy favorable for device
avigation such as the distal cervical internal carotid artery
nd the carotid artery terminus. Although ﬁrst reports on
echanical thrombectomy included the use of aspiration
atheters [12,13], only few systematic data have been pub-
ished on this approach so far. A recent single-center study
eported on 22 patients (mean NIHSS 18) treated with aspira-
ion thrombectomy alone with a recanalization rate of 81.9%
nd a good clinical outcome in 45.5% [14].
enumbra System. The Penumbra System (Penumbra,
lmeda, USA) is a modiﬁcation of the proximal aspiration
echnique. It has been FDA approved for clot removal in
cute stroke treatment in 2007. It consists of a reperfusion
atheter attached to continuous aspiration via a dedicated
umping system. A microwire with an olive-shaped tip,
alled separator, is used to fragmentize the thrombus from
roximal to distal and to avoid obstruction of the aspiration
atheter by cleaning the catheter tip of clot fragments. Both
eperfusion catheter and separator are available in various
izes and diameters (0.26—0.51 in.) to adjust the device to
ifferent anatomical settings and to allow thrombectomy
ven in distal branches such as M2 segments.
The Penumbra System has been investigated in several
ingle-center and multicenter trials. The Penumbra Pivotal
troke Trial [15] prospectively evaluated 125 stroke patients
mean NIHSS 18) within 8 h after onset of symptoms. Suc-
essful recanalization of the target vessel was achieved in
1.6%. Despite the relatively high recanalization rate, favor-
ble clinical outcomewas achieved in only 25% of all patients
nd in 29% of patients with successful recanalization. Overall
ortality was 32.8% and sICH occurred in 11.2% with serious
dverse events in 3.2%. The high recanalization rate in con-
unction with the poor clinical outcome in this trial sparked
he discussion on the impact of recanalization using mechan-
cal thrombectomy. However, some single-center studies
eported more favorable clinical results with the Penumbra
ystem and then the Pivotal Trial with successful recanal-
zation in 93%, good clinical outcome in 48% and reduced
ortality of 11% [16].
istal thrombectomy
ompared to IAT and the use of proximal devices, the use
f distal thrombectomy devices is technically more com-
lex. An 8 F sheath and balloon catheter of similar size are
sed. After placement of the balloon catheter in the internal
arotid artery, a microcatheter (0.18—0.27 in.) is navigated
cross the occlusion site to pass the thrombus. The device
s then introduced into the microcatheter and unsheathed
ehind the thrombus. This approach applies the retrieval
orce to the distal base of the thrombus. The device and
hrombus are then retracted into the guide catheter under
alloon occlusion and additional aspiration.
56 P. Mordasini et al.
Figure 1 74-year-old male patient 4.5 h after acute onset of right hemiplegia and aphasia, at admission NIHSS 18, bridging therapy.
(A) Digital subtraction angiogram of the left internal carotid artery, illustrating proximal occlusion (arrow) of the middle cerebral
artery (MCA). (B) Application of a stent-retriever: a microcatheter and microwire are advanced beyond the occlusion side (arrow)
and placed into the distal branches of the MCA (*). (C) Angiogram immediately after placement of a stent-retriever (Solitaire
FR) covering the occlusion (arrow). The device compresses the thrombus and creates a channel; a temporary bypass to the distal
branches of the MCA (*). (D) After retrieval of the device 5min later complete recanalization of the MCA main trunk (arrow) and
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che distal braches. (E) The stent-retriever device (arrow) after
*). The patient recovered to NIHSS 5 after 24 h, mRS 1 after 90
Clinical observations have shown that thrombectomy
sing distal devices has the risk of potentially dislodging
hrombotic material during retrieval from the occlusion site
nto a previously unaffected vascular territory. Such embolic
vents may worsen the patient’s neurological condition.
herefore, distal thrombectomy devices are regularly used
n combination with proximal balloon occlusion in the inter-
al carotid artery in conjunction with aspiration from the
uiding catheter in order to reduce the risk of thromboem-
olic events during retrieval. Furthermore, vasospasm and
essel wall damage have been reported more frequently in
ssociation with distal thrombectomy devices. Various distal
hrombectomy devices with brush-like, basket-like or coil-
ike designs have been advocated in the past (e.g. Catch,
alt, Montmorency, France; Phenox pCR and CRC, Bochum,
ermany), with most of them only available in Europe. The
argest clinical experience has been reported on the Merci
etrieval System (Concentric Medical, Mountain View, USA),
hich is the ﬁrst device of this group to receive FDA approvaln 2004.
erci Retrieval System. The Merci Retrieval System is
omehow the pioneer of intracranial device development
or acute stroke treatment. FDA approval was based on the
w
o
muccessful thrombectomy with the entangled clot from the MCA
s.
ulticenter Mechanical Embolus Removal in Cerebral
schemia (MERCI) trial [17]. 151 patients (mean NIHSS 20)
ere evaluated within 8 h after onset of symptoms, who
ere ineligible for standard IAT. Successful recanalization
as achieved in 46% of patients with favorable clinical out-
ome in 27.7%. Mean procedure time was 2.1 h. Clinically
igniﬁcant procedural complications occurred in 7.1% and
ate of sICH was 7.8%. The Multi-MERCI trial [18] was a
rospective, multicenter, single-arm registry that included
64 patients (mean NIHSS 19) within 8 h after onset of symp-
oms. In contrast to the MERCI trial, patients with persistent
arge vessel occlusion after IV tPA were also included in the
tudy, adjunctive IAT using rtPA and the use of other mechan-
cal recanalization techniques and new generation of Merci
evices were allowed. Recanalization success was 57.3%
sing the Merci device alone and 69.5% in conjunction with
ther treatment modalities. Favorable clinical outcome was
chieved in 36% of patients with clinical signiﬁcant compli-
ations in 5.5% and sICH in 9.8%. Mean time to recanalization
as 1.6 h.
The introduction of the Merci device was a landmark
f mechanical recanalization in acute stroke treat-
ent. Both MERCI trials demonstrated a signiﬁcantly
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better clinical outcome in patients with successful recanal-
ization.
Stent retriever. The most recent developments for
mechanical acute stroke treatment are self-expandable,
retrievable, stent-like thrombectomy devices. They com-
bine the advantages of intracranial stent placement with
immediate ﬂow restoration without the need of permanent
device implantation and the advantages of a thrombectomy
system with the ability of deﬁnitive clot removal. This con-
cept offers a promising new treatment option for acute
ischemic stroke with high recanalization rates, marked
reduction in procedure time and a marked elevation in
the rate of favorable clinical outcome. Stent retrievers are
applied in a comparable manner to that of intracranial
stents. The occlusion site is passed with a microcatheter
(0.21—0.27 in.) and the device is deployed over the entire
thrombus. Due to its radial force, the device compresses
the thrombus against the contralateral vessel wall leading
to immediate partial ﬂow restoration to the distal vessel
territory. After an embedding time of 3—10min the device
is retrieved. As for distal thrombectomy devices the use of
proximal balloon occlusion and aspiration during retrieval is
recommended in order to avoid thromboembolic events.
Several stent retrievers with different designs are cur-
rently under development or evaluated in ﬁrst clinical trials
(Trevo, Concentric Medical, Mountain View, USA; PULSE and
3D Separator, Penumbra, Almeda, USA; Revive, Micrus, USA;
Aperio, Acandis, Pforzheim, Germany; Bonnet and pREset,
Phenox, Bochum, Germany).
The ﬁrst dedicated combined ﬂow restoration and
thrombectomy device for acute stroke treatment was the
Solitaire FR (ev3, Irvine, USA). The device is a modiﬁca-
tion of the Solitaire AB Neurovascular Remodeling Device,
originally developed for stent-assisted coil treatment of
wide-necked intracranial aneurysms. Within a short period
of time several in vivo and clinical studies have reported
about the application of the Solitaire FR for acute stroke
treatment (Fig. 1).
The ﬁrst clinical experience was published by Castano
et al. [19] in 2010 reporting their initial treatment of 20
patients within 8 h after onset of symptoms. Successful
recanalization was achieved in 90% of patients with a favor-
able clinical outcome in 45%. Mean procedure time was
short with 50min. sICH occurred in 10%. Several other small
case series using various stent retrievers have shown simi-
lar promising successful recanalization rates (88—91%) and
fast procedural times (42—55min) with comparable rates of
favorable clinical outcome (42—54%) [20—22]. Rohde et al.
[23] reported their preliminary experience with the Revive
system (Micrus Endovascular, San Jose, USA) in the treat-
ment of large vessel occlusion in 10 patients (mean NIHSS
19). The design of the Revive system consists of a closed
basket at the distal end of the stent in order to enhance
clot removal. Successful recanalization (TICI 2b or 3) was
achieved in all patients with favorable outcome in 60% of
patients after 30 days. The Solitaire FR with the Intention
for Thrombectomy (SWIFT) trial is a randomized trial com-
paring the efﬁcacy and safety of the Solitaire FR with that
of the Merci device. The SWIFT trial was halted by the data
monitoring board early in 2011 after inclusion of 126 patients
of anticipated 250 patients. The results have not yet been
published, but favorable results for the Solitaire FR can be57
ssumed. The Solitaire FR is currently evaluated in the Soli-
aire FR Thrombectomy for Acute Revascularization (STAR)
rial, a prospective, multicenter, single-arm study with an
nrolment goal of 200 patients. The study includes patients
ithin 8 h after symptom onset ineligible for or with failed
V rtPA as a bridging therapy or thrombectomy as initial
reatment. First results are expected in mid-2012.
onclusion
mmediate ﬂow restoration is the principle goal of ischemic
troke therapy and is associated with better clinical out-
ome and reducedmortality. The introduction of mechanical
pproaches has expanded the time window for stroke treat-
ent and broadened the spectrum of stroke patients for
reatment. The latest results of MT using stent-retrievers
emonstrate high recanalization rates in conjunction with
hort recanalization times and a low-risk device-related
evere adverse event. Furthermore, recent data show that
he increased recanalization rate of MT improves clinical
utcome.
The future role of MT in acute stroke treatment is not
lear yet. Considering the poor recanalization rate and clin-
cal outcome of patients with proximal vessel occlusions and
arge thrombus burden (e.g. internal carotid artery occlu-
ion), MT is likely to become a ﬁrst-line treatment.
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